Sign up for our monthly newsletter!

Get the latest information and inspirational stories for caregivers, delivered directly to your inbox.

Sage's phase 2 Alzheimer's drug shows signs of cognitive improvement—but there's a catch

Fierce Biotech

description

SAGE-718 is being studied in a phase 2 trial called Luminary in patients with mild cognitive impairment and mild dementia due to Alzheimer’s. The study, which is part of Sage’s CogNEXt program evaluating the drug to treat cognitive deficits in multiple indications, was geared towards determining safety.

See full story at Fierce Biotech

© 2025 MCI and Beyond. All rights reserved.